uniQure Inc.

Contributing Author

Recent Articles by uniQure Inc.

Jun-25	uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares QURE GlobeNewswire
Jun-23	uniQure Announces Pricing of Upsized $225 Million Public Offering QURE GlobeNewswire
Jun-22	uniQure Announces $150 Million Proposed Public Offering QURE GlobeNewswire
Jun-19	uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy QURE GlobeNewswire
Jun-17	uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease QURE +78.44% GlobeNewswire
May-05	uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates QURE GlobeNewswire
Apr-30	uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease QURE +19.25% GlobeNewswire
Apr-28	uniQure to Announce First Quarter 2026 Financial Results QURE GlobeNewswire
Mar-02	uniQure Announces 2025 Financial Results and Provides Recent Company Updates QURE -32.82% GlobeNewswire
Mar-02	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease QURE -32.82% GlobeNewswire
Feb-23	uniQure to Announce 2025 Financial Results QURE GlobeNewswire
Feb-06	uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in a-Gal A Enzyme Activity in Patients with Fabry Disease QURE GlobeNewswire
Jan-09	uniQure Announces Type A Meeting Scheduled with FDA QURE +9.37% GlobeNewswire
Dec-04	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease QURE -10.75% GlobeNewswire
Nov-10	uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update QURE -5.90% GlobeNewswire
Nov-06	uniQure to Announce Third Quarter 2025 Financial Results QURE +5.56% GlobeNewswire
Nov-03	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease QURE -49.34% GlobeNewswire
Sep-29	uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares QURE +9.37% GlobeNewswire
Sep-25	uniQure Announces Pricing of Upsized $300 Million Public Offering QURE GlobeNewswire
Sep-24	uniQure Announces $200 Million Proposed Public Offering QURE +247.73% GlobeNewswire
Sep-24	uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding QURE +247.73% GlobeNewswire
Sep-24	uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease QURE +247.73% GlobeNewswire
Sep-05	uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in a-Gal A Enzyme Activity in Patients with Fabry Disease QURE GlobeNewswire
Jul-29	uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress QURE -8.68% GlobeNewswire
Jul-22	uniQure to Announce Second Quarter 2025 Financial Results QURE GlobeNewswire
Jun-11	uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer QURE GlobeNewswire
Jun-02	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease QURE GlobeNewswire
May-29	uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) QURE GlobeNewswire
May-09	uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress QURE GlobeNewswire
May-05	uniQure to Announce First Quarter 2025 Financial Results QURE +7.58% QURE -27.75% GlobeNewswire

uniQure Inc.

Recent Articles by uniQure Inc.

Upgrade your Finviz experience